PT - JOURNAL ARTICLE AU - Hao, Meng AU - Jiang, Shuai AU - Li, Xiangnan AU - Wang, Shuming AU - Li, Yi AU - Tang, Jingdong AU - Hu, Zixin AU - Zhang, Hui TI - Association of red cell distribution width to albumin ratio with risk of all-cause and cause-specific mortality: two prospective cohort studies AID - 10.1101/2024.01.10.24301123 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.10.24301123 4099 - http://medrxiv.org/content/early/2024/01/12/2024.01.10.24301123.short 4100 - http://medrxiv.org/content/early/2024/01/12/2024.01.10.24301123.full AB - Background The red cell distribution width to albumin ratio (RAR) has emerged as a reliable prognostic marker for mortality in various diseases. However, whether RAR is associated with mortality remains unknown in the general population.Objective Explore whether RAR is associated with all-cause and cause-specific mortality, and to elucidate the dose-response relationship between them.Methods This study included 50622 participants aged 18+ years from US National Health and Nutrition Examination Survey (NHANES), and 418950 participants aged 37+ years from UK Biobank. The potential association between RAR and the risk of all-cause and cause-specific mortality was evaluated by Cox proportional hazard models. Restricted cubic spline regressions were applied to estimate the possible nonlinear relationships.Results NHANES documented 7590 deaths over a median follow-up of 9.4 years, and UK Biobank documented 36793 deaths over a median follow-up of 14.5 years. In multivariable analysis, elevated RAR were significantly associated with a higher risk of all-cause mortality (NHANES: hazard ratio [HR]: 1.86, 95% confidence interval [CI]: 1.81-1.93; UK Biobank: HR: 2.01, 95% CI: 1.96-2.06), as well as mortality due to malignant neoplasms, heart disease, cerebrovascular diseases, respiratory diseases, diabetes mellitus, and others in both the two cohorts (all P-value < 0.05).Conclusions Higher baseline RAR was strongly and independently associated with increased risk of all-cause and cause-specific mortality in the general population. RAR was a promising indicator that simply, reliably, and inexpensively accessible for identifying high-risk of mortality in clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Foundation of China-Youth Science Fund (82301768, 32300533, 32100510), the Shanghai Sailing Program (23YF1430500), and the Shanghai Rising-Star Program (21QB1400900).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data from NHANES are available at www.cdc.gov/nchs/nhis/index.htm, and data from UK Biobank are available on application at www.ukbiobank.ac.uk/register-apply.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from NHANES are available at www.cdc.gov/nchs/nhis/index.htm, and data from UK Biobank are available on application at www.ukbiobank.ac.uk/register-apply.